http://www.atrium-innov.com/ Atrium Biotechnologies is a leading developer, manufacturer and marketer of value-added products for the cosmetics, pharmaceutical, chemical and nutrition industries. We market a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products. en-ca Copyright 2007 daily http://www.atrium-innov.com/en/investisseurs/communique.php?id=72 PRESS RELEASE FOR IMMEDIATE RELEASE ATRIUM GENERATES STRONG GROWTH DURING THE SECOND QUARTER Significant increase in revenues and net earnings from continued operations of 165% and 157% respectively All amounts are in US dollars. Quebec City (Quebec), August 7, 2008 – Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries, disclosed today its financial results for the second quarter of 2008. Quarterly highlights: • Sale of AI&SC Division completed, allowing to focus activities in the promising health and nutrition sector; • Strong organic growth in sales and earnings; • Strong growth also contributed by the two recent acquisitions, Mucos and MCO. Integrations are proceeding smoothly; • Strong financial position and well positioned to pursue the acquisition strategy; • Favorable short-term outlook. During the quarter ended June 30, 2008, Atrium recorded revenues from continuing operations of $74.5 million, which represents an increase of 165% compared to revenues of $28.2 million for the corresponding quarter in 2007. Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the second quarter of 2008 increased by 128% to $18.2 million compared to $8.0 million for the same period in 2007. For the quarter ended June 30, 2008, net earnings from continuing operations were $10.7 million compared to $4.2 million for the same period in 2007, an increase of 157%. The Company’s total net earnings were $43.9 million compared to net earnings of $6.6 million for the corresponding period in 2007. For the second quarter of 2008, net earnings per share on a diluted basis rose to $1.33 per share, compared to $0.20 per share for the same period in 2007. Net earnings and net earnings per share in 2008 include a net gain of $30.9 million on the sale of the AI&SC Division. For the six-month period ended June 30, 2008, revenues from continuing operations were $140.3 million, up 119% from $64.1 million for the corresponding period in 2007. EBITDA from continuing operations for the first half of 2008 was $36.6 million, an increase of 108% compared to $17.6 million for the same period last year. For the first half of 2008, total net earnings increased by 284% to $58.6 million generating fully diluted earnings per share of $1.77, compared to $15.2 million and $0.47 per share for the first six months of 2007. “We are extremely satisfied with our results for the second quarter, confirming the soundness of our strategic development plan. Strong organic growth exceeding our target, combined with the benefits of our recent acquisitions, allows us to be optimistic for the remainder of 2008. Moreover, completing the sale of our Active Ingredients and Specialty Chemicals Division is providing us all the financial flexibility required to pursue our growth strategy through acquisitions in the promising sector of specialties health and nutrition products,” said Mr. Pierre Fitzgibbon, Atrium’s President and Chief Executive Officer. For the second quarter of 2008, cash flows from continuing operating activities, before changes in non-cash working capital items, were $12.2 million, an increase of 149% compared to $4.9 million for the same period of the preceding year. For the six-month period ended June 30, 2008, cash flows from continuing operating activities, before changes in non-cash working capital items, were $23.9 million, an increase of 115% compared to $11.1 million for the same period in 2007. As at June 30, 2008, the Company had a total debt amounting to $144 million as the Company has a revolving credit facility that provides $300 million of borrowing capacity. In addition, through an unsecured loan, the Company has additional capacity of $35.9 million that can be used in whole or in part by December 31, 2008 according to the amendment signed on May 21, 2008. Discontinued Operations – Active Ingredients and Specialty Chemicals (AI&SC) Division On May 22, 2008, Atrium completed the sale of its Active Ingredients and Specialty Chemicals Division for total proceeds of $166.4 million in cash, subject to a post-closing working capital adjustment. Atrium has become a health and nutrition pure play and the net proceeds from the transaction will provide the Company with increased financial flexibility to pursue its development strategy. The AI&SC Division’s operations from April 1, 2008 to May 21, 2008, which are included in the second quarter of 2008 and presented as discontinued operations, generated revenues of $34.3 million, compared to revenues of $48.3 million for the complete quarter of 2007. For the same periods, EBITDA was $3.4 million in 2008 compared to $4.7 million in 2007. For the period between January 1, 2008 and May 21, 2008, revenues from discontinued operations were $102.3 million compared to $107.0 million for the six-month period ended June 30, 2007. For the same periods, EBITDA from discontinued operations was $9.8 million in 2008 compared to $10.0 million in 2007. About Atrium Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. Conference Call and Webcast Atrium will hold its quarterly conference call and webcast to discuss its second quarter 2008 on Thursday, August 7, 2008 at 10:00 a.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3418, 514-807-8791 or 1-800-732-0232. A live webcast is also available via the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days. A copy of Atrium’s interim unaudited financial statements will also be available on the Company’s website. Caution Regarding Non-GAAP Measures This press release is based on reported earnings in accordance with Canadian generally accepted accounting principles (GAAP). It is also based on earnings before interest, income taxes, depreciation and amortization (EBITDA) and gross margin. These measures do not have a standardized meaning prescribed by GAAP; therefore, other issuers using these terms may calculate them differently. Management believes that a significant portion of the users of its Consolidated Financial Statements and MD&A analyze the Company's results based on these performance measures. Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law. Investor Relations: Mario Paradis Vice-President and Chief Financial Officer Tel.: (418) 652-1116 mparadis@atrium-innov.com Media Relations: Frédéric Tremblay HKDP Tel.: (514) 395-0375, ext. 234 ftremblay@hkdp.qc.ca -30- Attachment: Financial summary ATRIUM GENERATES STRONG GROWTH DURING THE SECOND QUARTER http://www.atrium-innov.com/en/investisseurs/communique.php?id=71 PRESS RELEASE FOR IMMEDIATE RELEASE Atrium Innovations to Present at Upcoming 28th Annual Canaccord Adams Global Growth Conference Quebec City, Canada, August 5, 2008 – Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries, today announced that its President and Chief Executive Officer, Mr. Pierre Fitzgibbon, will present a company overview at the upcoming 28th Annual Canaccord Adams Global Growth Conference on Tuesday, August 12, 2008 at 11 am (eastern time), in the San Francisco Room of the InterContinental Boston Hotel in Boston, MA. A live webcast of Mr. Fitzgibbon’s presentation will be available on our website at www.atrium innov.com in the Investors section. A replay will also be available for a period of 90 days on the Company’s website. About Atrium Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. -30- Source: Atrium Innovations Inc. Investor Relations: Mario Paradis Vice President and Chief Financial Officer (418) 652-1116 ext. 334 mparadis@atrium-innov.com Media Relations: Frédéric Tremblay HKDP (514) 395-0375 ext. 234 ftremblay@hkdp.qc.ca ATRIUM INNOVATIONS TO PRESENT AT UPCOMING 28TH ANNUAL CANACCORD ADAMS GLOBAL GROWTH CONFERENCE http://www.atrium-innov.com/en/investisseurs/communique.php?id=70 PRESS RELEASE FOR IMMEDIATE RELEASE Atrium Innovations to Hold 2008 Second Quarter Financial Results Conference Call and Webcast on August 7, 2008 Quebec City, Canada, July 29, 2008 – Atrium Innovations Inc. (TSX: ATB) will hold its quarterly conference call and webcast at 10:00 a.m. Eastern time on August 7, 2008. The call will follow the press release of Atrium’s 2008 second quarter results which will be issued earlier that day. Participants may access the call by using the following numbers: 416-644-3418, 514 807-8791 or 800-732-0232 or via the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website www.atrium-innov.com in the “Investors” section for a period of 30 days. About Atrium Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. -30- Source: Atrium Innovations Inc. Investor Relations: Mario Paradis Vice President and Chief Financial Officer (418) 652-1116 ext. 334 mparadis@atrium-innov.com Media Relations: Frédéric Tremblay HKDP (514) 395-0375 ext. 234 ftremblay@hkdp.qc.ca ATRIUM INNOVATIONS TO HOLD 2008 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST ON AUGUST 7, 2008 http://www.atrium-innov.com/en/investisseurs/communique.php?id=69 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]ATRIUM COMPLETES THE SALE OF ITS ACTIVE INGREDIENTS AND SPECIALTY CHEMICALS DIVISION[/b] Quebec City, Canada, May 22, 2008 – In accordance with the terms previously announced on April 4, 2008, Atrium Innovations Inc. “Atrium” (TSX: ATB) today announced that it has completed the sale of its Active Ingredients and Specialty Chemicals division for total proceeds of US$166.4 million in cash, subject to a post-closing working capital adjustment. Atrium is now a health and nutrition pure-play and the net proceeds from the transaction will provide the Company with better financial flexibility to pursue its corporate strategy. About Atrium Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. -30- Investor Relations: Media Relations: Mario Paradis Frédéric Tremblay Vice President and Chief Financial Officer HKDP Tel.: (418) 652-1116, ext. 334 Tel.: (514) 395-0375, ext. 234 mparadis@atrium-innov.com ftremblay@hkdp.qc.ca ATRIUM COMPLETES THE SALE OF ITS ACTIVE INGREDIENTS AND SPECIALTY CHEMICALS DIVISION http://www.atrium-innov.com/en/investisseurs/communique.php?id=68 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]ATRIUM SHOWS A STRONG FINANCIAL PERFORMANCE FOR ITS FIRST QUARTER[/b] [i]Increase of 98% in net earnings from continuing operations during the first quarter of 2008 to reach 10.5 million US dollars[/i] [i]All amounts in US dollars[/i] [b]Quebec (Quebec), May 6, 2008[/b] – Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of added value products for health and nutrition industries, announced today his financial results for the first quarter of 2008. During the quarter ended March 31, 2008, Atrium recorded revenues from continuing operations of $65.8 million, which represents an increase of 83.2% compared to revenues of $35.9 million for the corresponding quarter in 2007. Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) from continuing operations for the first quarter of 2008 increased by 90.8% to $18.4 million when compared to US$9.6 million for the same period in 2007. For the quarter ended March 31, 2008, net earnings from continuing operations rose by 97.8% to US$10.5 million when compared to $5.3 million for the same period in 2007. The Company’s total net earnings were US$14.7 million, an increase of 70.8% when compared to net earnings of $8.6 million for the corresponding period in 2007. Net earnings per share on a diluted basis for the first quarter of 2008 rose by 69.2% to $0.44 per share, compared to $0.26 per share for the same period in 2007. “We are very satisfied with the strong financial results for the first quarter as the Mucos integration is going according to plan and as we experienced solid organic growth in the quarter. We have begun the integration of Multicare B.V., which was acquired on February 15. This acquisition respects perfectly our strategic acquisition program. Furthermore we remain confident that we will finalize the sale of the Active Ingredients and Specialty Chemicals Division (“AI&SC”) in the upcoming weeks as announced on April 4, allowing us to focus on our Health and Nutrition Division, and generating value for our shareholders” said Mr. Pierre Fitzgibbon, Atrium’s President and Chief Executive Officer. “The sale of the division at an attractive price will give us the means to execute our strategy to become the leader in the high end nutritional supplements“said Mr. Pierre Laurin, Chairman of Atrium. Cash flows from continuing operations (before changes in non-cash working capital items) for the first quarter of 2008 were $11.7 million, an increase of 87.3% compared to $6.2 million for the same period of the preceding year. As at March 31, 2008, the Company had a total debt amounting to $325 million while the Company had a revolving credit facility that provides $350 million of borrowing capacity with the possibility to increase it up to $425 million. In addition, the Company has additional capacity, through an unsecured loan, of $35.6 million which can be used in whole or in part from now until May 21, 2008. [b]Discontinued Operations – Active Ingredients and Specialty Chemicals (AI & SC) Division [/b] For the quarter ended March 31, 2008, the Active Ingredients & Specialty Chemicals Division, presented as discontinued operations, generated revenues of $68.0 million, which is an increase of 15.6% compared to revenues of $58.8 million recorded for the same period in 2007. For the first quarter of 2008, the EBITDA was $6.5 million compared to an EBITDA of $5.3 million for the corresponding period in 2007, an increase of 21.2 %. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of added value products for health and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 600 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. [b]Conference Call and Webcast[/b] Atrium will hold its quarterly conference call and webcast to discuss its first quarter 2008 on Tuesday May 6, 2008 at 2:00 p.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3416, 514-807-8791 or 1-800-731-5319. A live webcast is also available via the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days. A copy of Atrium’s interim unaudited financial statements will also be available on the Company’s website. [i]Caution Regarding Non-GAAP Measures This press release is based on reported earnings in accordance with Canadian generally accepted accounting principles (GAAP). It is also based on earnings before interest, income taxes, depreciation and amortization (EBITDA) and gross margin. These measures do not have a standardized meaning prescribed by GAAP; therefore, other issuers using these terms may calculate them differently. Management believes that a significant portion of the users of its Consolidated Financial Statements and MD&A analyze the Company's results based on these performance measures. Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.[/i] -30- Investor Relations: Media Relations: Mario Paradis Frédéric Tremblay Vice-President and Chief Financial Officer HKDP Tel.: (418) 652-1116 (514) 395-0375, ext. 234 mparadis@atrium-innov.com ftremblay@hkdp.qc.ca STRONG PERFORMANCE - INCREASE OF 98% IN NET EARNINGS FROM CONTINUING OPERATIONS DURING THE FIRST QUARTER OF 2008 http://www.atrium-innov.com/en/investisseurs/communique.php?id=67 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6[/b] [b]Quebec City, Canada, April 28, 2008 [/b]– Atrium Innovations Inc. (TSX: ATB) will hold its quarterly conference call and webcast at 2:00 p.m. Eastern time on May 6, 2008. The call will follow the press release of Atrium’s 2008 first quarter results issued earlier that day. Participants may access the call by using the following numbers: 416-644-3416, 514-807-8791 or 800-731-5319 or via the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website www.atrium-innov.com in the “Investors” section for a period of 30 days. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the health and nutrition industry. The Company focuses primarily on growing segments of the health and nutrition market which is benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of health and nutrition finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. [i]Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.[/i] -30- Source: Atrium Innovations Inc. Investor Relations: Media Relations: Mario Paradis Frédéric Tremblay Vice President and Chief Financial Officer HKDP (418) 652-1116 ext. 334 (514) 395-0375 ext. 234 mparadis@atrium-innov.com ftremblay@hkdp.qc.ca Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6 http://www.atrium-innov.com/en/investisseurs/communique.php?id=66 [b]P R E S S R E L E A S E FOR IMMEDIATE RELEASE[/b] [b]ATRIUM ANNOUNCES THE SALE OF ITS ACTIVE INGREDIENTS AND SPECIALTY CHEMICALS DIVISION TO BECOME A HEALTH AND NUTRITION PURE-PLAY[/b] [b]Quebec City, Canada, April 4, 2008 [/b]– Atrium Innovations Inc. “Atrium” (TSX: ATB) today announced that, as a result of the strategic re-evaluation process announced on December 18, 2007, it has entered into a definitive agreement to sell its Active Ingredients and Specialty Chemicals division to AXA Private Equity for US$155 million in cash, subject to working capital adjustments. Total proceeds from the sale, including excess cash in the business, are expected to be US$165 million, subject to working capital adjustments. The completion of the transaction is subject to certain customary conditions, including receipt of a limited number of regulatory approvals, but is not subject to any financing condition. The parties expect the transaction to be completed by mid May. Following the transaction, the main office of the Active Ingredients and Specialty Chemicals division will remain in Quebec City under the leadership of Charles Boulanger, President of the Active Ingredients and Specialty Chemicals division, and its existing management team. The Company believes that the transaction will bring significant benefits: - Atrium will become a health and nutrition pure-play, benefiting from the healthy living and ageing population trends; - Focus Atrium’s management and financial resources to achieve its strategic objectives, including its goal of becoming a world leader in its health and nutrition industry; and - Provide financial flexibility to continue to play a consolidator role in the higher growth and highly fragmented sector with future accretive acquisitions. “We are pleased to have entered into this agreement with AXA Private Equity, allowing us to execute efficiently on our announced strategic process to divest the division. This transaction will allow us to optimize the creation of shareholder value by focusing exclusively on the Health and Nutrition industry, where we intend to continue to play the role of a strategic consolidator in a conducive industry environment,” said Mr. Pierre Fitzgibbon, President and Chief Executive Officer of Atrium. “This transaction is a good outcome for both our shareholders and the division’s employees as it provides compelling value and certainty while maintaining the main office in Quebec City under the leadership of its existing management team,” said Mr. Pierre Laurin, Chairman of Atrium. “We are delighted to have the opportunity to support the strategic development of Atrium’s Active Ingredients and Specialty Chemicals business. We appreciate its positioning as a provider of value-added products and services, the diversity of its clients and suppliers portfolio and the outstanding management team led by Charles Boulanger. We plan to double the size of the company through the next five years, mainly in Europe and in North America, thanks to a dynamic organic growth and a focused acquisition strategy,“ said Eric Neuplanche, Managing Director at AXA Private Equity. Lazard acted as financial advisor to Atrium in the transaction. [b]Conference Call and Webcast[/b] Atrium will hold a conference call and webcast to discuss this transaction on Monday April 7, 2008 at 10:00 a.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3416, 514-807-8791 or 1-800-732-9303. A live webcast will also be available on the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America, Europe and Asia. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com [b] About AXA Private Equity[/b] AXA Private Equity – an AXA Investment Managers company – is one of the world’s leading private equity firms. AXA Private Equity offers investors a broad selection of high performance funds for every market segment: Buyout, Expansion Capital, Venture Capital, Co-investments, Infrastructure, Mezzanine, Primary, Early Secondary and Secondary Funds of Funds. The firm manages and/or advises on more than $22 billion of funds on behalf of leading international investors. Backed by its offices in Paris, Frankfurt, London, Milan, New York and Singapore, AXA Private Equity stands out from the competition through the expertise of its teams and its broad international presence. The firm maintains a constant focus on transparency, performance and sustainable profitability. Additional information about AXA Private Equity is available on its Web site at www.axaprivateequity.com [i]Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forwardlooking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law[/i][i].[/i] -30- Investor Relations: Media Relations: Pierre Fitzgibbon Frédéric Tremblay President and Chief Executive officer HKDP Tel.: (418) 652-1116 Tel.: (514) 395-0375, ext. 234 pfitzgibbon@atrium-innov.com ftremblay@hkdp.qc.ca AXA Private Equity: Catherine Gros catherine.gros@image7.fr Flore Larger flarger@image7.fr Tel.: +33 1 53 70 74 70 ATRIUM ANNOUNCES THE SALE OF ITS ACTIVE INGREDIENTS AND SPECIALTY CHEMICALS DIVISION TO BECOME A HEALTH AND NUTRITION PURE-PLAY http://www.atrium-innov.com/en/investisseurs/communique.php?id=65 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]ATRIUM APPOINTS MARIO PARADIS AS VICE PRESIDENT AND CHIEF FINANCIAL OFFICER [/b] [i]The Company has also strengthened its sales and marketing team with two new appointments to complement its resources in the United States and in Europe [/i] [b]Quebec (Quebec), February 29, 2008[/b] – Mr. Pierre Fitzgibbon, President and Chief Executive Officer of Atrium Innovations Inc. (TSX: ATB), is pleased to announce the appointment of Mr. Mario Paradis, CA, to the position of Vice President and Chief Financial Officer of the Company. Mr Paradis will begin his new duties in early April and is succeeding Mr. John Dempsey, who will contribute during the transition as a consultant to the company. Previously for a period of 9 years, Mr. Paradis held positions with different levels of responsibilities at Æterna Zentaris. He acted as Director of Finance and Vice President, Finance and Administration for a period of 8 years and was the Corporate Secretary for the last 4 years. In May 2007, he was named Senior Vice President, Administration and Legal Affairs and was a key strategic executive to the CEO and executive management team in developing long term strategy, including M&A transactions. Prior to joining Æterna Zentaris, Mr. Paradis worked for 11 years with PricewaterhouseCoopers where he successively held positions in audit, tax and finally in certification as Senior Director. “Mario Paradis brings the Company solid expertise in financial operations management, strategy and finance in the health industry. These qualities perfectly meet the present and future needs of Atrium, which is a rapidly growing company that is pursuing a dynamic acquisitions program requiring solid integration capabilities. We are very happy to welcome Mr. Paradis to the Atrium team. I would also like to thank John for his valuable contribution to Atrium’s development in recent years, particularly in the preparation of Atrium’s initial public offering in 2005. We are also pleased to know that we can benefit from his expertise during the transition period in his role as a consultant to the Company’s executive team. One of John’s tasks will be to assist the Company with the divestiture of its AI & SC Division,” underlined Mr. Fitzgibbon. [b]Sales and Marketing team appointments[/b] Furthermore, Atrium has recruited two high-calibre individuals in sales and marketing to support its business development plan in Europe and the United States. Mr. René Augstburger has been appointed Marketing Vice President, Europe. In this new role, Mr. Augstburger will be responsible for coordinating the Company’s sales and marketing development in the European region. Mr. Augstburger has held several management positions in companies operating in the health sector. Just prior to joining Atrium, Mr. Augstburger was General Manager of Arkopharma Canada. Previously, he also held executive positions at various companies in the health sector, including the German company Heel GmbH where he successively held the positions of Managing Director of Heel’s subsidiaries in Africa and the United States. Atrium also welcomes Mr. David Belaga to its sales and marketing team. He will oversee commercial development in North America of the Mucos product line, which includes Wobenzym® N, a well-known product currently sold in Germany and some Eastern European countries. Mr. Belaga has 20 years experience in sales and marketing within the health and wellness industry, in which he also held key management responsibilities. Previously, he has worked for companies such as Amerifit Nutrition and American Home Products (now Wyeth), among others. During his career, he has successfully launched several product brands, including Estroven, now one of the best selling nutritional supplements in the American market. “These appointments will supply Atrium with the complementary resources and expertise required to pursue the dynamic development of its two operating platforms in Europe and United States that offer very high commercial potential for the Company. Our development strategy is based on two main pillars – sustained organic growth and acquisitions of financially strong companies that market high quality products. Our recent acquisition of Multicare B.V., as well as Mucos Emulsions GmbH last July, are examples of this strategy in action. There is also a great deal of development potential in our current and new product lines, notably Wobenzym® N for which we are just starting to implement our focused marketing plan in the United States,” said Mr. Serge Yelle, Atrium’s Executive Vice President – Health and Nutrition Division. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 700 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. [i]Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.[/i] -30- Investor Relations: Media Relations: Pierre Fitzgibbon Frédéric Tremblay President and Chief Executive Officer HKDP Tel.: (418) 652-1116 (514) 395-0375, ext. 234 pfitzgibbon@atrium-innov.com ftremblay@hkdp.qc.ca ATRIUM APPOINTS MARIO PARADIS AS VICE PRESIDENT AND CHIEF FINANCIAL OFFICER http://www.atrium-innov.com/en/investisseurs/communique.php?id=64 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]ATRIUM REFOCUSES ITS OPERATIONS ON THE HEALTH AND NUTRITION SECTOR AND POSTS STRONG NET EARNINGS GROWTH[/b] [i]Increase of 44% in net earnings from continuing operations during Fiscal 2007 and 74% growth for the fourth quarter of 2007[/i] All amounts in US dollars [b]Quebec (Quebec), February 29, 2008 [/b]– Atrium Innovations Inc. (TSX: ATB) today discloses its annual financial results and also reconfirms the strategic refocusing of its business operations. Atrium intends to concentrate its operations uniquely in the health and nutrition sector (presented here as continuing operations) and, consequently, has decided to divest its Active Ingredients & Specialty Chemicals Division (presented as discontinued operations). This decision, which was made in the best interest of both divisions, follows a strategic re-evaluation process of the AI & SC Division initiated by the Company on December 18, 2007. It became clear that focusing on one sector would be the best option for Atrium to optimize its future development and profitability. During the fiscal year ended December 31, 2007, Atrium recorded revenues from continuing operations of US$172.8 million, which is an increase of 50.7% compared to revenues of US$114.7 million posted for the preceding fiscal year. Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) from continuing operations for fiscal 2007 increased by 66.1% to reach US$46.0 million, compared to US$27.7 million for the same period in 2006. For the year ended December 31, 2007, net earnings from continuing operations rose by 43.8% to US$24.8 million, compared to US$17.2 million for the same period in 2006. The Company’s total net earnings were US$35.7 million, which is an increase of 34.0% compared to net earnings of US$26.7 million for the corresponding period in 2006. Net earnings per share on a diluted basis for fiscal 2007 rose by 32.9% to reach US$1.09, compared to US$0.82 per share for the preceding fiscal year. “We ended the year 2007 on a strong note. On one hand, we have posted strong financial results and on the other hand, we have undertaken the strategic refocusing of our operations to concentrate on the highly promising health and nutrition sector. This decision should prove greatly beneficial to the Company’s future. We are confident that we will be able to complete the divestiture of our Active Ingredients & Specialty Chemicals Division during the second quarter at a fair price for our shareholders reflecting the full value of this division. Furthermore, during the current fiscal year we would like to pursue our development plan to be driven by a sustained organic growth and new acquisitions that respect our rigorous strategic and financial criteria,” said Mr. Pierre Fitzgibbon, Atrium’s President and Chief Executive Officer. Cash flows from continuing operations (before changes in non-cash working capital items) for fiscal 2007 were US$26.6 million, an increase of 31.9% compared to US$20.1 million for the same period of the preceding year. The Company has a revolving credit facility that provides US$350 million of borrowing capacity under certain conditions and the possibility of increasing this capacity to US$425 million. As at December 31, 2007, the Company had drawn down US$265.5 million under this credit facility. In addition, the Company has supplementary capacity, through an unsecured loan, of US$36.9 million which can be used in whole or in part from now until May 21, 2008. “The Company’s financial situation is solid. Because of the capacity available through our current financings and the net proceeds from the eventual divestiture of our Active Ingredients & Specialty Chemicals Division, we should have the financial resources required to support our future growth,” added Mr. Fitzgibbon. [b]Discontinued Operations – Active Ingredients and Specialty Chemicals (AI & SC) Division [/b] Reporting now the AI & SC Division as discontinued operations has changed the distribution of head office expenses. These expenses are now 100% absorbed by Health & Nutrition, rather than being distributed between the two divisions. For the year ended December 31, 2007, the Active Ingredients & Specialty Chemicals Division, presented under operations to be sold, generated revenues of US$221.6 million, which is an increase of 15.8% compared to revenues of US$191.4 million recorded for the same period in 2006. For fiscal 2007, the EBITDA was US$19.1 million compared to an EBITDA of US$17.1 million for the corresponding period in 2006, an increase of 11.8 %. This growth is attributable to strong organic growth and the acquisition of Amisol in May 2006. [b]Financial results for the fourth quarter of 2007[/b] For the three month period ended December 31, 2007, the Company recorded revenues under continuing operations of US$57.9 million, compared to revenues of US$28.9 million for the same period of the preceding fiscal year, for an increase of 100.5 %. The EBITDA rose by 114.8% to reach US$13.7 million, compared to US$6.4 million for the same period in 2006. Net earnings from continuing operations in the fourth quarter of 2007 were US$8.1 million, for an increase of 73.9% compared to net earnings from continuing operations of $4.6 million for the corresponding quarter in 2006. This growth is mainly attributable to Mucos acquisition in July 2007 and strong organic growth. The weighted average number of shares outstanding was in the fourth quarter of 2007 was 31.1 million compared to 30.6 million for the same period in 2006. For the three month period ended December 31, 2007, the Active Ingredients & Specialty Chemicals Division, presented as discontinued operations, generated revenues of US$64.5 million, for an increase of 20.2% compared to revenues of US$53.7 million recorded for the same period in 2006. For fiscal 2007, the EBITDA was US$4.5 million compared to an EBITDA of US$4.4 million for the corresponding period in 2006, an increase of 3.9%. This increase is attributable to organic growth and the acquisition of Amisol in May 2006. Overall, for the three-month period ended December 31, 2007, the Company’s net earnings were US$10.7 million, or US$0.34 per share, which is an increase of 52.4% compared to net earnings of US$7.0 million, or US$0.23 per share, for the corresponding period in 2006. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 700 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. [b]Conference Call and Webcast[/b] Atrium will hold its quarterly conference call and webcast to discuss its fourth quarter and full year 2007 on Friday February 29, 2008 at 1:30 p.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3420, 514-807-8791 or 1-800-731-5774. A live webcast is also available via the Company’s website at www.atrium-innov.com in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days. A copy of Atrium’s interim unaudited financial statements is available on the Company’s website. [b]Caution Regarding Non-GAAP Measures[/b] This press release is based on reported earnings in accordance with Canadian generally accepted accounting principles (GAAP). It is also based on earnings before interest, income taxes, depreciation and amortization (EBITDA) and gross margin. These measures do not have a standardized meaning prescribed by GAAP; therefore, other issuers using these terms may calculate them differently. Management believes that a significant portion of the users of its Consolidated Financial Statements and MD&A analyze the Company's results based on these performance measures. [b]Cautionary Note and Forward-Looking Statements[/b] This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law. -30- Investor Relations: Media Relations: Pierre Fitzgibbon Frédéric Tremblay President and Chief Executive Officer HKDP Tel.: (418) 652-1116 (514) 395-0375, ext. 234 pfitzgibbon@atrium-innov.com ftremblay@hkdp.qc.ca [b]Attachment: Financial summary available in pdf in the [i]Additional Documentation [/i]section[/b] ATRIUM REFOCUSES ITS OPERATIONS ON THE HEALTH AND NUTRITION SECTOR AND POSTS STRONG NET EARNINGS GROWTH http://www.atrium-innov.com/en/investisseurs/communique.php?id=63 [b]PRESS RELEASE FOR IMMEDIATE RELEASE [/b] [b]ATRIUM ACQUIRES MULTICARE B.V., A NETHERLANDS-BASED COMPANY[/b] [i]This latest acquisition opens new commercial opportunities for Atrium in the large European market[/i] Quebec City, Canada, February 19, 2008 - Atrium Innovations Inc. (TSX: ATB) is pleased to announce the acquisition of Multicare B.V. (“Multicare” or the “Company”) which has its headquarters in Almere, located near Amsterdam, in the Netherlands. Multicare, through its subsidiary MCO Health B.V. (“MCO Health”), manufactures and markets a complete range of nutritional supplements under different brands among which Orthica is by far the most important. The Company which has annual sales of about US$22 million (15 million euros), sells its products primarily in the Netherlands and they are mainly marketed to healthcare practitioners and are also distributed through drugstores. Atrium will acquire Multicare for a total of US$24.8 million (17 million euros). Of this total, US$23.4 million (16 million euros) will be paid in cash and the remainder will be paid by the issuance of 81,128 newly issued Atrium common shares to Multicare’s President and CEO. Moreover, Multicare has a bank debt of US$6.4 million US (4 million euros). “We are very happy with this acquisition, which is perfectly in line with our strategic development objectives, in addition to respecting our financial criteria. MCO Health markets high quality products and enjoys an excellent reputation with its customers. This Company, which has posted strong financial results and is backed by a seasoned executive team, has a business model that can be naturally integrated into Atrium’s own model. With MCO Health, Atrium now has a new European platform that complements last July’s acquisition of Mucos Emulsions GmbH,” said Mr. Pierre Fitzgibbon, Atrium’s President and Chief Executive Officer. “We are also very pleased to be able to count on the support of Mr. Mathew Sänger, President and Chief Executive Officer of Multicare, who will continue in this position following the transaction. [b]About Multicare[/b] Multicare, through its subsidiary MCO Health, develops, markets and distributes over 300 high-quality science based food supplement products mainly recommended by health care practitioners. Since its establishment in 1994, Multicare and its subsidiary MCO Health have become one of the leading players within the Dutch food supplement sector and generates over 95% of its sales within The Netherlands. Multicare employs a highly dedicated and exceptionally trained team of 66 employees focused on providing customers with the utmost level of value and service. The state of the art facility situated in the city of Almere has been recognized by the industry for pursuing the highest level of quality production based on ISO 9001 standards and has received top certifications such as the HACCP (Hazard Analysis Critical Control Points) certificate as well as the BRC (British Retail Consortium) certificate for the complete product development, purchasing and production process. [b]About Atrium[/b] Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com. [i]Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.[/i] -30- Investor Relations: Media Relations: John Dempsey Frédéric Tremblay Vice-President, Finance, and Chief Financial Officer HKDP Tel.: (418) 652-1116, ext. 287 (514) 395-0375, ext. 234 jdempsey@atrium-innov.com ftremblay@hkdp.qc.ca ATRIUM ACQUIRES MULTICARE B.V., A NETHERLANDS-BASED COMPANY